NDAORALTABLETPriority Review
Approved
Oct 1958
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 4h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DIABINESE (chlorpropamide) is an oral first-generation sulfonylurea antidiabetic agent approved in 1958 for type 2 diabetes management. It works by stimulating pancreatic beta cells to increase insulin secretion, lowering blood glucose levels. This legacy oral medication represents one of the earliest classes of synthetic diabetes treatments.
LOE Approaching
Declining
This legacy product is in advanced decline with minimal commercial momentum, suggesting limited team expansion and focus on managed transition rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DIABINESE offers minimal career advancement opportunity given zero linked job openings and advanced LOE status. This product is best suited for professionals managing legacy brands or nearing career transition, not for those seeking growth, visibility, or upward mobility.
Brand Manager (legacy)Field Sales Representative
Worked on DIABINESE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.